Australian Pharmaceutical Industries Limited engages in the wholesale distribution of pharmaceutical, medical, health, beauty, and lifestyle products to pharmacies primarily in Australia.
Australian Pharmaceutical Industries Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$1.52|
|52 Week High||AU$1.05|
|52 Week Low||AU$1.55|
|1 Month Change||3.75%|
|3 Month Change||8.57%|
|1 Year Change||43.40%|
|3 Year Change||-12.89%|
|5 Year Change||-20.63%|
|Change since IPO||-35.32%|
Recent News & Updates
Australian Pharmaceutical Industries (ASX:API) Takes On Some Risk With Its Use Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Is Australian Pharmaceutical Industries Limited (ASX:API) A Good Dividend Stock?
Dividend paying stocks like Australian Pharmaceutical Industries Limited ( ASX:API ) tend to be popular with investors...
How Does Australian Pharmaceutical Industries' (ASX:API) CEO Salary Compare to Peers?
Richard Vincent became the CEO of Australian Pharmaceutical Industries Limited ( ASX:API ) in 2017, and we think it's a...
|API||AU Healthcare||AU Market|
Return vs Industry: API exceeded the Australian Healthcare industry which returned 11.5% over the past year.
Return vs Market: API exceeded the Australian Market which returned 20.2% over the past year.
Stable Share Price: API is less volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: API's weekly volatility (5%) has been stable over the past year.
About the Company
Australian Pharmaceutical Industries Limited engages in the wholesale distribution of pharmaceutical, medical, health, beauty, and lifestyle products to pharmacies primarily in Australia. It also retails health and beauty products to consumers through a network of Priceline and Priceline Pharmacy franchise stores, and company owned Priceline stores in Australia; sells beauty products through Clear Skincare network of clinics in Australia and New Zealand; and manufactures and distributes pharmaceutical and toiletry goods to New Zealand, Australian, and Asian markets, as well as provides cosmetic products and non-invasive aesthetic beauty services. The company was founded in 1910 and is based in Camberwell, Australia.
Australian Pharmaceutical Industries Fundamentals Summary
|API fundamental statistics|
Is API overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|API income statement (TTM)|
|Cost of Revenue||AU$3.49b|
Last Reported Earnings
Feb 28, 2021
Next Earnings Date
Oct 28, 2021
|Earnings per share (EPS)||-0.029|
|Net Profit Margin||-0.36%|
How did API perform over the long term?See historical performance and comparison
2.0%Current Dividend Yield
Is Australian Pharmaceutical Industries undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: API (A$1.52) is trading above our estimate of fair value (A$0.89)
Significantly Below Fair Value: API is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: API is unprofitable, so we can't compare its PE Ratio to the Australian Healthcare industry average.
PE vs Market: API is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate API's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: API is good value based on its PB Ratio (1.6x) compared to the AU Healthcare industry average (2.1x).
How is Australian Pharmaceutical Industries forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: API is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: API is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: API's is expected to become profitable in the next 3 years.
Revenue vs Market: API's revenue (2.2% per year) is forecast to grow slower than the Australian market (5.5% per year).
High Growth Revenue: API's revenue (2.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: API's Return on Equity is forecast to be low in 3 years time (9.6%).
How has Australian Pharmaceutical Industries performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: API is currently unprofitable.
Growing Profit Margin: API is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: API is unprofitable, and losses have increased over the past 5 years at a rate of 22% per year.
Accelerating Growth: Unable to compare API's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: API is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (61.3%).
Return on Equity
High ROE: API has a negative Return on Equity (-3.13%), as it is currently unprofitable.
How is Australian Pharmaceutical Industries's financial position?
Financial Position Analysis
Short Term Liabilities: API's short term assets (A$938.1M) exceed its short term liabilities (A$727.6M).
Long Term Liabilities: API's short term assets (A$938.1M) exceed its long term liabilities (A$313.7M).
Debt to Equity History and Analysis
Debt Level: API's debt to equity ratio (40.9%) is considered high.
Reducing Debt: API's debt to equity ratio has increased from 30% to 40.9% over the past 5 years.
Debt Coverage: API's debt is well covered by operating cash flow (43.1%).
Interest Coverage: API's interest payments on its debt are well covered by EBIT (5.3x coverage).
What is Australian Pharmaceutical Industries's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: API's dividend (1.97%) isn’t notable compared to the bottom 25% of dividend payers in the Australian market (2.27%).
High Dividend: API's dividend (1.97%) is low compared to the top 25% of dividend payers in the Australian market (5.32%).
Stability and Growth of Payments
Stable Dividend: API's dividend payments have been volatile in the past 10 years.
Growing Dividend: API's dividend payments have not increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: API is paying a dividend but the company is unprofitable.
Future Payout to Shareholders
Future Dividend Coverage: API's dividends in 3 years are forecast to be covered by earnings (65.9% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Richard C. Vincent, B.Bus, (Accountancy), CPA, has been Chief Executive Officer, Managing Director and Executive Director at Australian Pharmaceutical Industries Limited since February 15, 2017. Mr. Vi...
CEO Compensation Analysis
Compensation vs Market: Richard's total compensation ($USD966.87K) is above average for companies of similar size in the Australian market ($USD736.11K).
Compensation vs Earnings: Richard's compensation has increased whilst the company is unprofitable.
Experienced Management: API's management team is considered experienced (4.8 years average tenure).
Experienced Board: API's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Australian Pharmaceutical Industries Limited's employee growth, exchange listings and data sources
- Name: Australian Pharmaceutical Industries Limited
- Ticker: API
- Exchange: ASX
- Founded: 1910
- Industry: Health Care Distributors
- Sector: Healthcare
- Market Cap: AU$748.837m
- Shares outstanding: 492.66m
- Website: https://www.api.net.au
- Australian Pharmaceutical Industries Limited
- 250 Camberwell Road
- Level 5
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/17 07:02|
|End of Day Share Price||2021/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.